GeneThera (GeneThera) Change In Working Capital : $0.48 Mil (TTM As of Sep. 2022)

View and export this data going back to 2000. Start your Free Trial

What is GeneThera Change In Working Capital?

GeneThera's change in working capital for the quarter that ended in Sep. 2022 was $0.12 Mil.

GeneThera's change in working capital for the fiscal year that ended in Dec. 2021 was $0.49 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

GeneThera Change In Working Capital Historical Data

The historical data trend for GeneThera's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneThera Change In Working Capital Chart

GeneThera Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Working Capital

Get a 7-Day Free Trial

0.52

0.65

0.51

0.75

0.49

GeneThera Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Working Capital	Get a 7-Day Free Trial															0.14	0.11	0.15	0.10	0.12

GeneThera Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.48 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

GeneThera Change In Working Capital Related Terms

Thank you for viewing the detailed overview of GeneThera's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneThera (GeneThera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035

Website

http://genetherainc.com

GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.

Executives

Avel Kolesnikov	director	11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr	10 percent owner	632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd	10 percent owner	CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner	director, officer: Chief Financial Officer	728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici	director, 10 percent owner, officer: Chief Executive Officer	3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry	director, 10 percent owner, officer: Chief Administative Officer	11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines